Skip to main content
51°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exscientia Ltd ADR
(NQ:
EXAI
)
4.840
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exscientia Ltd ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 03, 2024
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...
Via
Benzinga
Exposures
Glyphosate
Six Of Seven AI Stock Categories Increased This Week
March 23, 2024
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia Earnings Preview
March 20, 2024
Via
Benzinga
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q4 2023
March 21, 2024
EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Exscientia Business and Financial Update for the Full Year 2023
March 21, 2024
From
Exscientia plc
Via
Business Wire
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
March 14, 2024
From
Exscientia plc
Via
Business Wire
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
March 04, 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy.
Via
InvestorPlace
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Grand View Research says the global
Via
Talk Markets
Exscientia to Present at Upcoming Investor Conferences in March
February 28, 2024
From
Exscientia plc
Via
Business Wire
Exscientia plc (EXAI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI Drug Hunter Firm Exscientia Fires Its CEO Over 'Inappropriate' Relationships with Two Employees
February 13, 2024
Exscientia terminates CEO Andrew Hopkins over inappropriate relationships with employees. Interim CEO appointed.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 12, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 12, 2024
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth reading about for Monday morning!
Via
InvestorPlace
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
February 07, 2024
From
Exscientia plc
Via
Business Wire
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 10, 2024
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.
Via
Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
January 02, 2024
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024.
Via
InvestorPlace
Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
January 02, 2024
From
Exscientia
Via
Business Wire
Top Picks 2024: Exscientia Plc
December 31, 2023
Founded in 2012 and based in Oxford, England, Exscientia Plc is using Artificial Intelligence to develop new medicines and is attracting high-quality partners. It has a rapidly growing pipeline of more...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Focused Drug Discovery Stocks Index Up 26% In December
December 29, 2023
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.
Via
Talk Markets
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
December 21, 2023
From
Exscientia plc
Via
Business Wire
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
December 17, 2023
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
December 11, 2023
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now
December 07, 2023
Exscientia has the potential to be a star collaborator and a profitable drug developer, too.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
December 06, 2023
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
December 05, 2023
From
Exscientia plc
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.